Cracking prostate cancer's code: An enzyme's central role in controlling subtypes and improving therapeutic response

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...
News Medical

PTGES3 emerges as key regulator of androgen receptor in prostate cancer

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Renal & Urology News

Dual Androgen Receptor Ligand Degrader, Antagonist Shows Efficacy in mCRPC

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
EurekAlert!

Study focuses on resistance to androgen receptor-targeted therapy in advanced prostate cancer

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
European Medical Journal

Circulating Tumour Cells Predict Taxane Resistance

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...
Medical Dialogues

Topical Clascoterone 5% Shows Significant Hair Regrowth Without Systemic Effects in topline data

Clascoterone 5% topical solution, an anti-androgen that targets the hair follicle androgen receptor without measurable ...